Extrapulmonary Soft-Tissue Fibrosis Resulting From Hypofractionated Stereotactic Body Radiotherapy for Pulmonary Nodular Lesions

Takatsugu Kawase, Atsuya Takeda, Etsuo Kunieda, Masaki Kokubo, Yoshifumi Kamikubo, Ryouchi Ishibashi, Tomoaki Nagaoka, Naoyuki Shigematsu, Atsushi Kubo

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: To clarify the incidence, symptoms, and timing of extrapulmonary fibrosis developing after hypofractionated stereotactic body radiotherapy. Patients and Methods: We analyzed 379 consecutive patients who underwent stereotactic body radiotherapy for lung tumors at four institutions between February 2001 and March 2007. The median follow-up time was 29 months (range, 1-72). We investigated the subjective and objective characteristics of the extrapulmonary masses, redelineated the origin tissue of each on the treatment planning computed tomography scan, and generated dose-volume histograms. Results: In 9 patients (2.4%), extrapulmonary masses were found 3-36 months (median, 14) after irradiation. Coexisting swelling occurred in 3 patients, chest pain in 2, thumb numbness in 1, and arm edema in 1 patient. Extrapulmonary masses occurred in 5 (5.4%) of 92 and 4 (1.4%) of 287 patients irradiated with a 62.5-Gy and 48.0-Gy isocenter dose, respectively. The mean and maximal dose to the origin tissue was 25.8-53.9 Gy (median, 43.7) and 47.5-62.5 Gy (median, 50.2), respectively. In 5 of 9 patients, the standardized uptake values on 18F-fluorodeoxyglucose-positron emission tomography was 1.8-2.8 (median, 2.2). Percutaneous needle biopsy was performed in 3 patients, and all the specimens showed benign fibrotic changes without malignant cells. Conclusion: All patients should be carefully followed after stereotactic body radiotherapy. The findings of any new lesion should prompt an assessment for radiation-induced extrapulmonary fibrosis before an immediate diagnosis of recurrence is made. Careful beam-shape modification and dose prescription near the thoracic outlet are required to prevent forearm neuropathy and lymphedema.

Original languageEnglish
Pages (from-to)349-354
Number of pages6
JournalInternational Journal of Radiation Oncology Biology Physics
Volume74
Issue number2
DOIs
Publication statusPublished - 2009 Jun 1

Fingerprint

pulmonary lesions
fibrosis
Radiosurgery
radiation therapy
Fibrosis
Lung
dosage
tomography
forearm
edema
Lymphedema
Hypesthesia
pain
chest
Thumb
Fluorodeoxyglucose F18
Needle Biopsy
outlets
Chest Pain
Forearm

Keywords

  • Fibrosis
  • Lung cancer
  • Radiation toxicity
  • Stereotactic body radiotherapy

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Extrapulmonary Soft-Tissue Fibrosis Resulting From Hypofractionated Stereotactic Body Radiotherapy for Pulmonary Nodular Lesions. / Kawase, Takatsugu; Takeda, Atsuya; Kunieda, Etsuo; Kokubo, Masaki; Kamikubo, Yoshifumi; Ishibashi, Ryouchi; Nagaoka, Tomoaki; Shigematsu, Naoyuki; Kubo, Atsushi.

In: International Journal of Radiation Oncology Biology Physics, Vol. 74, No. 2, 01.06.2009, p. 349-354.

Research output: Contribution to journalArticle

Kawase, Takatsugu ; Takeda, Atsuya ; Kunieda, Etsuo ; Kokubo, Masaki ; Kamikubo, Yoshifumi ; Ishibashi, Ryouchi ; Nagaoka, Tomoaki ; Shigematsu, Naoyuki ; Kubo, Atsushi. / Extrapulmonary Soft-Tissue Fibrosis Resulting From Hypofractionated Stereotactic Body Radiotherapy for Pulmonary Nodular Lesions. In: International Journal of Radiation Oncology Biology Physics. 2009 ; Vol. 74, No. 2. pp. 349-354.
@article{65f93e5b51f640d68e638f0fb60f608d,
title = "Extrapulmonary Soft-Tissue Fibrosis Resulting From Hypofractionated Stereotactic Body Radiotherapy for Pulmonary Nodular Lesions",
abstract = "Purpose: To clarify the incidence, symptoms, and timing of extrapulmonary fibrosis developing after hypofractionated stereotactic body radiotherapy. Patients and Methods: We analyzed 379 consecutive patients who underwent stereotactic body radiotherapy for lung tumors at four institutions between February 2001 and March 2007. The median follow-up time was 29 months (range, 1-72). We investigated the subjective and objective characteristics of the extrapulmonary masses, redelineated the origin tissue of each on the treatment planning computed tomography scan, and generated dose-volume histograms. Results: In 9 patients (2.4{\%}), extrapulmonary masses were found 3-36 months (median, 14) after irradiation. Coexisting swelling occurred in 3 patients, chest pain in 2, thumb numbness in 1, and arm edema in 1 patient. Extrapulmonary masses occurred in 5 (5.4{\%}) of 92 and 4 (1.4{\%}) of 287 patients irradiated with a 62.5-Gy and 48.0-Gy isocenter dose, respectively. The mean and maximal dose to the origin tissue was 25.8-53.9 Gy (median, 43.7) and 47.5-62.5 Gy (median, 50.2), respectively. In 5 of 9 patients, the standardized uptake values on 18F-fluorodeoxyglucose-positron emission tomography was 1.8-2.8 (median, 2.2). Percutaneous needle biopsy was performed in 3 patients, and all the specimens showed benign fibrotic changes without malignant cells. Conclusion: All patients should be carefully followed after stereotactic body radiotherapy. The findings of any new lesion should prompt an assessment for radiation-induced extrapulmonary fibrosis before an immediate diagnosis of recurrence is made. Careful beam-shape modification and dose prescription near the thoracic outlet are required to prevent forearm neuropathy and lymphedema.",
keywords = "Fibrosis, Lung cancer, Radiation toxicity, Stereotactic body radiotherapy",
author = "Takatsugu Kawase and Atsuya Takeda and Etsuo Kunieda and Masaki Kokubo and Yoshifumi Kamikubo and Ryouchi Ishibashi and Tomoaki Nagaoka and Naoyuki Shigematsu and Atsushi Kubo",
year = "2009",
month = "6",
day = "1",
doi = "10.1016/j.ijrobp.2008.08.072",
language = "English",
volume = "74",
pages = "349--354",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Extrapulmonary Soft-Tissue Fibrosis Resulting From Hypofractionated Stereotactic Body Radiotherapy for Pulmonary Nodular Lesions

AU - Kawase, Takatsugu

AU - Takeda, Atsuya

AU - Kunieda, Etsuo

AU - Kokubo, Masaki

AU - Kamikubo, Yoshifumi

AU - Ishibashi, Ryouchi

AU - Nagaoka, Tomoaki

AU - Shigematsu, Naoyuki

AU - Kubo, Atsushi

PY - 2009/6/1

Y1 - 2009/6/1

N2 - Purpose: To clarify the incidence, symptoms, and timing of extrapulmonary fibrosis developing after hypofractionated stereotactic body radiotherapy. Patients and Methods: We analyzed 379 consecutive patients who underwent stereotactic body radiotherapy for lung tumors at four institutions between February 2001 and March 2007. The median follow-up time was 29 months (range, 1-72). We investigated the subjective and objective characteristics of the extrapulmonary masses, redelineated the origin tissue of each on the treatment planning computed tomography scan, and generated dose-volume histograms. Results: In 9 patients (2.4%), extrapulmonary masses were found 3-36 months (median, 14) after irradiation. Coexisting swelling occurred in 3 patients, chest pain in 2, thumb numbness in 1, and arm edema in 1 patient. Extrapulmonary masses occurred in 5 (5.4%) of 92 and 4 (1.4%) of 287 patients irradiated with a 62.5-Gy and 48.0-Gy isocenter dose, respectively. The mean and maximal dose to the origin tissue was 25.8-53.9 Gy (median, 43.7) and 47.5-62.5 Gy (median, 50.2), respectively. In 5 of 9 patients, the standardized uptake values on 18F-fluorodeoxyglucose-positron emission tomography was 1.8-2.8 (median, 2.2). Percutaneous needle biopsy was performed in 3 patients, and all the specimens showed benign fibrotic changes without malignant cells. Conclusion: All patients should be carefully followed after stereotactic body radiotherapy. The findings of any new lesion should prompt an assessment for radiation-induced extrapulmonary fibrosis before an immediate diagnosis of recurrence is made. Careful beam-shape modification and dose prescription near the thoracic outlet are required to prevent forearm neuropathy and lymphedema.

AB - Purpose: To clarify the incidence, symptoms, and timing of extrapulmonary fibrosis developing after hypofractionated stereotactic body radiotherapy. Patients and Methods: We analyzed 379 consecutive patients who underwent stereotactic body radiotherapy for lung tumors at four institutions between February 2001 and March 2007. The median follow-up time was 29 months (range, 1-72). We investigated the subjective and objective characteristics of the extrapulmonary masses, redelineated the origin tissue of each on the treatment planning computed tomography scan, and generated dose-volume histograms. Results: In 9 patients (2.4%), extrapulmonary masses were found 3-36 months (median, 14) after irradiation. Coexisting swelling occurred in 3 patients, chest pain in 2, thumb numbness in 1, and arm edema in 1 patient. Extrapulmonary masses occurred in 5 (5.4%) of 92 and 4 (1.4%) of 287 patients irradiated with a 62.5-Gy and 48.0-Gy isocenter dose, respectively. The mean and maximal dose to the origin tissue was 25.8-53.9 Gy (median, 43.7) and 47.5-62.5 Gy (median, 50.2), respectively. In 5 of 9 patients, the standardized uptake values on 18F-fluorodeoxyglucose-positron emission tomography was 1.8-2.8 (median, 2.2). Percutaneous needle biopsy was performed in 3 patients, and all the specimens showed benign fibrotic changes without malignant cells. Conclusion: All patients should be carefully followed after stereotactic body radiotherapy. The findings of any new lesion should prompt an assessment for radiation-induced extrapulmonary fibrosis before an immediate diagnosis of recurrence is made. Careful beam-shape modification and dose prescription near the thoracic outlet are required to prevent forearm neuropathy and lymphedema.

KW - Fibrosis

KW - Lung cancer

KW - Radiation toxicity

KW - Stereotactic body radiotherapy

UR - http://www.scopus.com/inward/record.url?scp=65449164903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65449164903&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2008.08.072

DO - 10.1016/j.ijrobp.2008.08.072

M3 - Article

VL - 74

SP - 349

EP - 354

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 2

ER -